VoiceNCT06612528
Transcranial Direct Current Stimulation on Singers Voice
A study testing tDCS and Flexible tube in water in people with Voice and Voice Range Profile, run by Universidade Federal de Pernambuco at 1 site in Brazil.
Trial summary
Transcranial direct current stimulation (tDCS) can be used to temporarily and reversibly modulate brain functions and is an increasingly utilized tool to investigate the relationships between brain and behavior. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Voice, Voice Range Profile, Voice Quality
- What is being tested?
- tDCS and Flexible tube in water
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 45 participants
- Where
- 1 siteBrazil
- Study dates
- 11 Mar 2024to 20 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Vocally healthy singers without formal singing education
Who cannot join
- Smokers
- Abnormalities in previous screening for voice symptoms
- Exhibited signs and symptoms of laryngeal, pharyngeal, or respiratory diseases at the time of collection
- Used neuroactive medications
- Had metallic implants in the cervical region or above
- Had any history of seizures or epilepsy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Transcranial Direct Current Stimulation on Singers' Voice
Transcranial direct current stimulation (tDCS) can be used to temporarily and reversibly modulate brain functions and is an increasingly utilized tool to investigate the relationships between brain and behavior. This study aimed to identify the effects of tDCS on vocal quality, vocal range, neuromotor functioning of the larynx and self-reported vocal effort in vocally healthy singers. This is a triple-blinded, sham-controlled, randomized clinical trial. The participants were randomized to one of the three tDCS groups (primary motor cortex, cerebellum or sham). In each group a voice training was applied at the same tDCS time. The three groups are: (i) cerebellum; (ii) primary motor cortex (M1); (iii) sham. The tDCS parameters in the active groups are anodal - 2mA for 20 minutes, at the sham group the stimuli are finished 30 secondes before starting. Volunteers passed for 10 intervention days and they were evaluated for vocal performance before the sessions, in the day 5 of intervention, the last day of intervention (day 10) and 1 month later for follow up evaluation. Voice recordings was taken to assess the following vocal parameters: vocal range profile (VRP) at weak and strong intensities; vocal quality (jitter, shimmer, irregularity, glottal-to-noise excitation ratio, CPPS,HNR, and dysphonia acoustic index) at weak, habitual, and strong intensities; laryngeal diadochokinesis, and self-reported vocal effort using the adapted Borg CR10 scale.
Read the detailed description
Data collection was conducted at the Applied Neuroscience Laboratory (LANA) of the Federal University of Pernambuco (UFPE).
This study includes vocally healthy individuals who are singers without formal music or singing training. Residents of the city of Recife and the Metropolitan Region, aged 18 to 45 years. The age range was chosen considering the period of maximum vocal efficiency To determine the sample size, a pilot study was conducted with 15 participants using the G*Power 3.1 program, considering a statistical power (β) of 80% and a significance level (α) of 5%. For this analysis, the primary vocal outcome variables (vocal range profile) was considered, and the sample size considered was 45, the largest value among the selected outcomes.
Singers without formal music training and without vocal complaints were included.
Individuals who were smokers or who presented signs and symptoms of laryngeal, pharyngeal or respiratory diseases at the time of data collection were excluded from the sample. Volunteers who were using neuroactive medications regularly, have metal implants in the cervical region or above, and had any history of seizures or epilepsy were also excluded.
The sample of singers was constituted by convenience through individuals who were singers without vocal complaints of both sexes, recruited through advertisements in electronic media. The first contact with the volunteers was through a screening to verify the eligibility criteria.
Added to tDCS is the vocal exercise, performed with the aid of a silicone tube with the following dimensions: 35cm in length, 1cm in diameter and 2mm in thickness, and with the distal end immersed at a distance of 3cm from the bottom of a 500ml plastic bottle containing 2/3 of water and with the spaces delimited. This study investigated the combined effects of tDCS and vocal exercises on singers voices. We conducted a clinical trial to examine the impact of concurrent neuromodulation and vocal training. Anodal tDCS was applied at 2mA for 20 minutes to three groups: (i) M1; (ii) Cerebellum; and (iii) sham. All groups performed vocal exercises using a flexible tube (FT) for a total of 12 minutes. Participants completed an adverse effects questionnaire after each session to report any discomfort. Vocal assessment was performed before the intervention to obtain results on vocal parameters, vocal range profile, and vocal effort, as well as on the 5th day after the start of the intervention, on the 10th day, and 1 month after the end of the activities. Voice recordings was taken to assess the following vocal parameters: vocal range profile (VRP) at weak and strong intensities; vocal quality (jitter, shimmer, irregularity, glottal-to-noise excitation ratio, CPPS,HNR, and dysphonia acoustic index) at weak, habitual, and strong intensities; laryngeal diadochokinesis, and self-reported vocal effort using the adapted Borg CR10 scale. The participants answered the Borg CR 10-BR scale questionnaire - adapted for vocal effort to assess the singers self-perception of the proposed tasks, however, the singers are instructed to report the intensity of the effort produced during the singing task of a song of their choice, according to their self-perceived difficulty.
In order to determine the volunteers who would be in each group, and for subsequent sample size calculation, a randomization was performed for 15 volunteers, by an external researcher, using a random table and adjusted to allow for counterbalancing. Codes were assigned to the groups, which were kept in opaque and numbered envelopes, available only to the person responsible for applying the tDCS. In this way, the evaluator, the therapist responsible for the vocal technique with a flexible tube immersed in water, and the singer remain blinded to the type of stimulation to which the participants was subjected. After performing the sample size calculation, a new randomization was performed to allocate the participants who continued in the data collection to complete the number of necessary volunteers.
The participants was allocated into three groups, namely: (i) M1; (ii) Cerebellum; (ii) sham. In all groups, 10 consecutive sessions of anodal tDCS associated with vocal exercise was performed, these only do not occur on weekends. For the application of tDCS in the groups: (i) M1, the stimulation electrode (anode) was positioned over C5 (international 10-20 EEG system) with the cathode (negative pole) positioned over the contralateral supraorbital region; (ii) Cerebellum, the stimulation electrode over the cerebellar cortex (inion, slightly to the right) and the reference electrode (cathode) was positioned over the right deltoid muscle; (ii) sham, the montage equivalent to cerebellar stimulation was performed, however in the sham stimulation there was an interruption of the stimulation 30 seconds after the start, thus the current intensity drops to zero mA, but the electrodes remained on the scalp of the volunteers until the end of the vocal exercise. The exercise with FT was performed for a total of 20 minutes (3 minutes of FT, four sequences, followed by 2 minutes of interval) in all groups. In the sham group, the electrodes was only removed after the end of the vocal exercises, so that the patient was unaware of the type of stimulation (real or sham) to which they were exposed. To blind the evaluator and therapist, a towel was placed over the volunteers head every day. Participants were instructed to sit comfortably while electrodes were placed on their scalp and tDCS stimulation was initiated. Following stimulation, participants performed vocal exercises using a flexible tube. The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range (soprano, mezzo-soprano, contralto, tenor, baritone, or bass). These scales were based on pre-recorded piano accompaniments.
The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy. This ensured that the vocal exercises concluded simultaneously with the tDCS session. Voice recordings was taken to assess the following vocal parameters: vocal range profile (VRP) at weak and strong intensities; vocal quality (jitter, shimmer, irregularity, glottal-to-noise excitation ratio, and dysphonia acoustic index) at weak, habitual, and strong intensities; laryngeal diadochokinesis, and self-reported vocal effort using the adapted Borg CR10 scale. This research was conducted in accordance with the ethical guidelines established by Brazils National Health Council (Resolution 466/12). The study was approved by the Human Research Ethics Committee of UFPE Health Sciences Center (number 5.758.856). Participants provided written informed consent after being fully informed about the studys objectives, procedures, potential risks, and benefits.
While the study posed minimal risks, participants might experience mild side effects from tDCS, such as tingling, itching, or burning sensations at the electrode sites. These side effects were carefully monitored. Additionally, some participants might experience discomfort during vocal exercises. However, these issues were addressed promptly.
Participants benefited from receiving guidance on vocal health and a personalized flexible tube. Data collected from vocal assessment software will be stored securely for at least 5 years. All data collected using Vocalgrama and VoxMetria software were analyzed using the respective software. In Vocalgrama, the following outcome measures were extracted: semitom range, and area of the vocal range profile. In VoxMetria, the following measures were extracted: jitter, shimmer, noise-to-harmonic ratio (NHR), and GNE from a 6-second sustained /ε/ vowel, excluding the first and last seconds. Cepstral analysis was conducted (CPPS and DAI). Audio recordings were made at a sampling rate of 44 kHz and 16-bit resolution. VoxMetria was also used to count the number of peaks in diadochokinetic tasks. Perceived effort was assessed using the Borg CR 10-BR scale adapted for vocal effort.
Data normality was assessed using the Shapiro-Wilk test. The non parmetric friedman repeated mensures was applied between the times of evaluation. All analyses was performed using SPSS (version 26.0, SPSS Inc, Chicago, USA) with a significance level of 5%.
- Conditions
- Voice, Voice Range Profile, Voice Quality
- Being tested
- tDCS, Flexible tube in water
- Keywords
- transcranial direct current stimulation, tDCS, Flexible tube, voice, singers
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tDCSDevice
Also called transcranial direct current stimulation
The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.
M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.
Flexible tube in waterDevice
Also called Lax vox, Flexible tube
The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.
The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.
| Study group | Role | What they receive |
|---|---|---|
| M1 and vocal exercise | Experimental | anodal tDCS over primary motor cortex associated with the vocal exercise using the flexible tube in water. Receives: Device: tDCS; Device: Flexible tube in water |
| Cerebellum and vocal exercise | Active comparator | anodal tDCS over cerebellum associated with the vocal exercise using the flexible tube in water. Receives: Device: tDCS; Device: Flexible tube in water |
| Sham and vocal exercise | Placebo comparator | tDCS sham associated with the vocal exercise using the flexible tube in water. Receives: Device: tDCS; Device: Flexible tube in water |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vocal Range Profile
Minimum fundamental frequency - f0; Maximum f0; Extension f0; Extension in Semitone; Minimum intensity; Maximum intensity and Area
Measured: From enrollment to the end of evaluation at 6 weeks
Secondary outcomes (1)
Vocal quality
jitter, shimmer, irregularity, Glottal-to-noise-excitation ratio, Dysphonia Acoustic Index
Measured: From enrollment to the end of evaluation at 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2024
- Study start11 Mar 2024
- Primary completion10 Oct 2025
- Study completion20 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for VoiceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were randomly assigned to one of three groups (M1, Cerebellum, or sham) using a computer-generated randomization list. All participants received 10 consecutive sessions of anodal tDCS combined with vocal exercises, except on weekends. Stimulation parameters and electrode placement varied by group: M1 - C5 (anode) and contralateral supraorbital (cathode); Cerebellum - cerebellar cortex (anode) and right deltoid (cathode); sham - identical electrode placement to the Cerebellum group, but with stimulation ceasing 30 seconds after onset. Vocal exercises consisted of four 3-minute bouts with a 2-minute rest between bouts. To maintain blinding, a towel was placed over the participants head during the procedure.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidade Federal de Pernambuco
- Sponsor type
- University, hospital or other
- Collaborators
- Coordination for the Improvement of Higher Education Personnel
- Responsible party
- Principal investigator, Kátia Monte-Silva, Universidade Federal de Pernambuco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06612528
- Sponsor's protocol ID
- 5.758.856
- Status last verified
- May 2026
- First submitted
- 21 Sep 2024
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Transcranial Direct Current Stimulation on Singers' Voice
- ClinicalTrials.gov ID
- NCT06612528
- Acronym / sponsor ID
- 5.758.856
- Conditions
- Voice, Voice Range Profile, Voice Quality
- Keywords
- transcranial direct current stimulation, tDCS, Flexible tube, voice, singers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Universidade Federal de PernambucoUniversity, hospital or other
- Collaborators
- Coordination for the Improvement of Higher Education Personnel
- Study start
- 11 Mar 2024 (actual)
- Primary completion
- 10 Oct 2025 (actual)
- Study completion
- 20 Dec 2025 (actual)
- First posted
- 25 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Transcranial direct current stimulation (tDCS) can be used to temporarily and reversibly modulate brain functions and is an increasingly utilized tool to investigate the relationships between brain and behavior. This study aimed to identify the effects of tDCS on vocal quality, vocal range, neuromotor functioning of the larynx and self-reported vocal effort in vocally healthy singers. This is a triple-blinded, sham-controlled, randomized clinical trial. The participants were randomized to one of the three tDCS groups (primary motor cortex, cerebellum or sham). In each group a voice training was applied at the same tDCS time. The three groups are: (i) cerebellum; (ii) primary motor cortex (M1); (iii) sham. The tDCS parameters in the active groups are anodal - 2mA for 20 minutes, at the sham group the stimuli are finished 30 secondes before starting. Volunteers passed for 10 intervention days and they were evaluated for vocal performance before the sessions, in the day 5 of intervention, the last day of intervention (day 10) and 1 month later for follow up evaluation. Voice recordings was taken to assess the following vocal parameters: vocal range profile (VRP) at weak and strong intensities; vocal quality (jitter, shimmer, irregularity, glottal-to-noise excitation ratio, CPPS,HNR, and dysphonia acoustic index) at weak, habitual, and strong intensities; laryngeal diadochokinesis, and self-reported vocal effort using the adapted Borg CR10 scale.
Detailed description
Data collection was conducted at the Applied Neuroscience Laboratory (LANA) of the Federal University of Pernambuco (UFPE).
This study includes vocally healthy individuals who are singers without formal music or singing training. Residents of the city of Recife and the Metropolitan Region, aged 18 to 45 years. The age range was chosen considering the period of maximum vocal efficiency To determine the sample size, a pilot study was conducted with 15 participants using the G*Power 3.1 program, considering a statistical power (β) of 80% and a significance level (α) of 5%. For this analysis, the primary vocal outcome variables (vocal range profile) was considered, and the sample size considered was 45, the largest value among the selected outcomes.
Singers without formal music training and without vocal complaints were included.
Individuals who were smokers or who presented signs and symptoms of laryngeal, pharyngeal or respiratory diseases at the time of data collection were excluded from the sample. Volunteers who were using neuroactive medications regularly, have metal implants in the cervical region or above, and had any history of seizures or epilepsy were also excluded.
The sample of singers was constituted by convenience through individuals who were singers without vocal complaints of both sexes, recruited through advertisements in electronic media. The first contact with the volunteers was through a screening to verify the eligibility criteria.
Added to tDCS is the vocal exercise, performed with the aid of a silicone tube with the following dimensions: 35cm in length, 1cm in diameter and 2mm in thickness, and with the distal end immersed at a distance of 3cm from the bottom of a 500ml plastic bottle containing 2/3 of water and with the spaces delimited. This study investigated the combined effects of tDCS and vocal exercises on singers voices. We conducted a clinical trial to examine the impact of concurrent neuromodulation and vocal training. Anodal tDCS was applied at 2mA for 20 minutes to three groups: (i) M1; (ii) Cerebellum; and (iii) sham. All groups performed vocal exercises using a flexible tube (FT) for a total of 12 minutes. Participants completed an adverse effects questionnaire after each session to report any discomfort. Vocal assessment was performed before the intervention to obtain results on vocal parameters, vocal range profile, and vocal effort, as well as on the 5th day after the start of the intervention, on the 10th day, and 1 month after the end of the activities. Voice recordings was taken to assess the following vocal parameters: vocal range profile (VRP) at weak and strong intensities; vocal quality (jitter, shimmer, irregularity, glottal-to-noise excitation ratio, CPPS,HNR, and dysphonia acoustic index) at weak, habitual, and strong intensities; laryngeal diadochokinesis, and self-reported vocal effort using the adapted Borg CR10 scale. The participants answered the Borg CR 10-BR scale questionnaire - adapted for vocal effort to assess the singers self-perception of the proposed tasks, however, the singers are instructed to report the intensity of the effort produced during the singing task of a song of their choice, according to their self-perceived difficulty.
In order to determine the volunteers who would be in each group, and for subsequent sample size calculation, a randomization was performed for 15 volunteers, by an external researcher, using a random table and adjusted to allow for counterbalancing. Codes were assigned to the groups, which were kept in opaque and numbered envelopes, available only to the person responsible for applying the tDCS. In this way, the evaluator, the therapist responsible for the vocal technique with a flexible tube immersed in water, and the singer remain blinded to the type of stimulation to which the participants was subjected. After performing the sample size calculation, a new randomization was performed to allocate the participants who continued in the data collection to complete the number of necessary volunteers.
The participants was allocated into three groups, namely: (i) M1; (ii) Cerebellum; (ii) sham. In all groups, 10 consecutive sessions of anodal tDCS associated with vocal exercise was performed, these only do not occur on weekends. For the application of tDCS in the groups: (i) M1, the stimulation electrode (anode) was positioned over C5 (international 10-20 EEG system) with the cathode (negative pole) positioned over the contralateral supraorbital region; (ii) Cerebellum, the stimulation electrode over the cerebellar cortex (inion, slightly to the right) and the reference electrode (cathode) was positioned over the right deltoid muscle; (ii) sham, the montage equivalent to cerebellar stimulation was performed, however in the sham stimulation there was an interruption of the stimulation 30 seconds after the start, thus the current intensity drops to zero mA, but the electrodes remained on the scalp of the volunteers until the end of the vocal exercise. The exercise with FT was performed for a total of 20 minutes (3 minutes of FT, four sequences, followed by 2 minutes of interval) in all groups. In the sham group, the electrodes was only removed after the end of the vocal exercises, so that the patient was unaware of the type of stimulation (real or sham) to which they were exposed. To blind the evaluator and therapist, a towel was placed over the volunteers head every day. Participants were instructed to sit comfortably while electrodes were placed on their scalp and tDCS stimulation was initiated. Following stimulation, participants performed vocal exercises using a flexible tube. The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range (soprano, mezzo-soprano, contralto, tenor, baritone, or bass). These scales were based on pre-recorded piano accompaniments.
The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy. This ensured that the vocal exercises concluded simultaneously with the tDCS session. Voice recordings was taken to assess the following vocal parameters: vocal range profile (VRP) at weak and strong intensities; vocal quality (jitter, shimmer, irregularity, glottal-to-noise excitation ratio, and dysphonia acoustic index) at weak, habitual, and strong intensities; laryngeal diadochokinesis, and self-reported vocal effort using the adapted Borg CR10 scale. This research was conducted in accordance with the ethical guidelines established by Brazils National Health Council (Resolution 466/12). The study was approved by the Human Research Ethics Committee of UFPE Health Sciences Center (number 5.758.856). Participants provided written informed consent after being fully informed about the studys objectives, procedures, potential risks, and benefits.
While the study posed minimal risks, participants might experience mild side effects from tDCS, such as tingling, itching, or burning sensations at the electrode sites. These side effects were carefully monitored. Additionally, some participants might experience discomfort during vocal exercises. However, these issues were addressed promptly.
Participants benefited from receiving guidance on vocal health and a personalized flexible tube. Data collected from vocal assessment software will be stored securely for at least 5 years. All data collected using Vocalgrama and VoxMetria software were analyzed using the respective software. In Vocalgrama, the following outcome measures were extracted: semitom range, and area of the vocal range profile. In VoxMetria, the following measures were extracted: jitter, shimmer, noise-to-harmonic ratio (NHR), and GNE from a 6-second sustained /ε/ vowel, excluding the first and last seconds. Cepstral analysis was conducted (CPPS and DAI). Audio recordings were made at a sampling rate of 44 kHz and 16-bit resolution. VoxMetria was also used to count the number of peaks in diadochokinetic tasks. Perceived effort was assessed using the Borg CR 10-BR scale adapted for vocal effort.
Data normality was assessed using the Shapiro-Wilk test. The non parmetric friedman repeated mensures was applied between the times of evaluation. All analyses was performed using SPSS (version 26.0, SPSS Inc, Chicago, USA) with a significance level of 5%.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Participants were randomly assigned to one of three groups (M1, Cerebellum, or sham) using a computer-generated randomization list. All participants received 10 consecutive sessions of anodal tDCS combined with vocal exercises, except on weekends. Stimulation parameters and electrode placement varied by group: M1 - C5 (anode) and contralateral supraorbital (cathode); Cerebellum - cerebellar cortex (anode) and right deltoid (cathode); sham - identical electrode placement to the Cerebellum group, but with stimulation ceasing 30 seconds after onset. Vocal exercises consisted of four 3-minute bouts with a 2-minute rest between bouts. To maintain blinding, a towel was placed over the participants head during the procedure.
| Arm | Type | Receives |
|---|---|---|
| M1 and vocal exercise | Experimental | Device: tDCS, Device: Flexible tube in wateranodal tDCS over primary motor cortex associated with the vocal exercise using the flexible tube in water. |
| Cerebellum and vocal exercise | Active comparator | Device: tDCS, Device: Flexible tube in wateranodal tDCS over cerebellum associated with the vocal exercise using the flexible tube in water. |
| Sham and vocal exercise | Placebo comparator | Device: tDCS, Device: Flexible tube in watertDCS sham associated with the vocal exercise using the flexible tube in water. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Vocally healthy singers without formal singing education
Key exclusion criteria (6 listed)
- Smokers
- Abnormalities in previous screening for voice symptoms
- Exhibited signs and symptoms of laryngeal, pharyngeal, or respiratory diseases at the time of collection
- Used neuroactive medications
- Had metallic implants in the cervical region or above
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tDCSAlso: transcranial direct current stimulationThe tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas. M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle. | Device | Cerebellum and vocal exercise, M1 and vocal exercise, Sham and vocal exercise |
| Flexible tube in waterAlso: Lax vox, Flexible tubeThe exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range. The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy. | Device | Cerebellum and vocal exercise, M1 and vocal exercise, Sham and vocal exercise |
Primary outcome
Vocal Range Profile
Time frame: From enrollment to the end of evaluation at 6 weeks
Minimum fundamental frequency - f0; Maximum f0; Extension f0; Extension in Semitone; Minimum intensity; Maximum intensity and Area
1 secondary outcome
Vocal quality
Time frame: From enrollment to the end of evaluation at 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
Related trials for Voice
Not yet recruiting
Starry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery
Congenital Heart Disease (CHD), Postoperative Sleep
Not yet recruiting
Endotracheal Tube Versus Transcartilage Needle Electrodes for Nerve Monitoring in Thyroid Surgery
Thyroid Diseases, Recurrent Laryngeal Nerve Injury
Not yet recruiting
GOT VOICE Feasibility With In-Person Group Singing
Elderly, Coronary Arterial Disease (CAD)
RecruitingObservational study
Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
Hearing Loss, Deafness
RecruitingObservational study
Voice-based Outcome Identification and Clinical Evaluation in Heart Failure
Heart Failure, Chronic Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing tDCS and Flexible tube in water in people with Voice and Voice Range Profile, run by Universidade Federal de Pernambuco at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vocal Range Profile (time frame: From enrollment to the end of evaluation at 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.